Article Text

Download PDFPDF

P68. A new EGFR - EpCAM bispecific antibody enhances the efficacy of adoptive T-cell therapy in a murine gastric tumour model
  1. S Kobold1,
  2. J Steffen1,
  3. S Grassmann1,
  4. R Castoldi2,
  5. J Schmollinger1,
  6. C Sustmann2,
  7. G Nierderfellner2,
  8. C Klein2,
  9. C Bourquin1 and
  10. S Endres1
  1. Aff1 Division of Clinical Pharmacology Munich Germany
  2. Aff2 grid.424277.0Roche Diagnostics GmBHDiscovery Oncology Penzberg Germany

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


A limiting step for adoptively transferred tumour-specific T cells is their recruitment from the blood circulation to the proximity of tumour cells and subsequent engagement in direct tumour cell contact. We hypothesised that a bispecific antibody recruiting T cells to a target antigen on tumour cells could enhance T-cell-tumour interaction and thus increase the efficacy of adoptively transferred T cells.

Material and methods

A new bispecific murine IgG2a antibody (BsAb) was generated that recognises EpCAM as a tumour antigen and truncated EGFR (D-EGFR) as an inert surface marker protein on transduced T cells. T cells from transgenic mice for TCR specific for the SV40 large T antigen (TCR-1) were retrovirally transduced with D-EGFR. S.c. tumors were induced in C57Bl/6 mice by injecting mGC8 cells derived from a syngeneic large T antigen expressing EpCAM-positive gastric tumor.


In vitro, the BsAb increased (4-fold) binding of transduced T cells to EpCAM positive tumour cells. In the presence of the BsAb, tumour-directed T cells efficiently lysed EpCAM-positive cells (83 % at a 10:1 effector to target ratio). In vivo, the antibody reached EpCAM+ tumour cells as evidenced by immunofluorescence. mGC8 tumour-bearing mice were treated twice with a combination of the BsAb and transduced TCR-I T cells. Tumour growth was significantly reduced for over 30 days (n=12) compared with control groups (transduced T-cells or BsAb alone) and survival was prolonged by > 30 days (p<0.001).


Co-administration of a BsAb bridging adoptively transferred tumour-specific T cells via an inert surface molecule to a tumour-associated surface antigen enhances the efficacy of therapeutic T cell transfer.